Kansas is currently home to 923 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Wichita, Kansas City, Overland Park and Topeka. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
NCT05143229
Recruiting
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: The University of Kansas Clinical Research Center, Fairway, Kansas
Conditions: Breast Cancer
Register for Updates
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
NCT02302742
Recruiting
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
Gender:
All
Ages:
All
Trial Updated:
05/08/2023
Locations: Hays Medical Center Dreiling-Schmidt Cancer Institute, Hays, Kansas
Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Register for Updates
A Post-market Clinical Study to Evaluate the Safety and Performance of the Carbon Fibre Reinforced Polyetheretherketone Metatarso-Phalangeal (MTP) Plate (CoLink® PCR MTP Plate) for the Treatment of Hallux Rigidus
NCT05692687
Recruiting
The clinical study involves the routine treatment of skeletally mature patients who have been diagnosed with hallux rigidus (stiffness of the first metatarso-phalangeal joint in the foot due to arthritis and degeneration of cartilage). It follows standard practice surgery to treat this condition. This type of degenerative arthritis affects the joint of the big toe (hallux) which is attached to the foot. Taking part in this research will involve collecting data of the surgery to remove damaged c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/03/2023
Locations: University of Kansas Medical Centre, Kansas City, Kansas
Conditions: Hallux Rigidus
Register for Updates
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
NCT04651634
Recruiting
The proposed study in patients with previously untreated locally advanced head and neck squamous cell carcinoma (HNSCC) is designed to evaluate the efficacy and safety of three different doses of MIT-001 compared to the placebo in prevention of oral mucositis (OM) in patients with HNSCC who are undergoing concurrent chemoradiotherapy (CCRT).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: Cancer Center of Kansas, Wichita, Kansas
Conditions: Oral Mucositis, Head and Neck Squamous Cell Carcinoma
Register for Updates
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
NCT02781883
Recruiting
The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission [CR], Complete Remission with incomplete hematologic recovery [CRi], Complete Remission with partial hematologic recovery [CRh], than venetoclax plus decitabine alone (by historical comparison) in participants with untreated AML that cannot or elect not to be treated with more intensive chemotherapy; (2) whether BP1001-based treat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: University of Kansas Cancer Center, Fairway, Kansas
Conditions: Acute Myeloid Leukemia (AML)
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: Children's Mercy Hospitals, Kansas City, Kansas
Conditions: Langerhans Cell Histiocytosis
Register for Updates
Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites
NCT04288921
Recruiting
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx Influenza A/B + RSV Test at Point of Care Testing Sites
Gender:
All
Ages:
All
Trial Updated:
03/10/2023
Locations: New Medical, Wichita, Kansas
Conditions: Influenza, Human, Respiratory Syncytial Virus Infections
Register for Updates
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
NCT03669614
Recruiting
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmaco... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
03/07/2023
Locations: Research Site, Overland Park, Kansas
Conditions: Cystic Fibrosis
Register for Updates
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
NCT04768868
Recruiting
A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2023
Locations: University of Kansas Clinical Research Center, Fairway, Kansas
Conditions: Advanced Solid Tumors
Register for Updates
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
NCT03533816
Recruiting
Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/07/2023
Locations: University of Kansas Cancer Center, Westwood, Kansas
Conditions: Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
Register for Updates
ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies
NCT04412616
Recruiting
This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) , to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of ZZ06 as a single agent in adult p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2023
Locations: Kansas University Cancer Center, Fairway, Kansas
Conditions: Advanced EGFR Positive Solid Tumor
Register for Updates
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
NCT03321188
Recruiting
This study will evaluate the use of Heated Intraperitoneal Chemotherapy (HIPEC) for primary treatment of ovarian cancer at the time of surgical debulking, to assess if intravenous (IV) chemotherapy can be started within 42 days of HIPEC and cytoreduction. All patients will receive cytoreductive surgery followed by a one-time closed HIPEC with cisplatin at 41-43 degrees Celsius for 90 minutes in the operating room. This is followed by 6 cycles of intravenous carboplatin and paclitaxel on an outpa... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/03/2023
Locations: The University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
Register for Updates